Bispecific antibody targeting PD-l1 and il-1 and use thereof

MYPI2025008327A0Undetermined Publication Date: 2024-12-28PHIL RIVERS TECH LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025008327
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-28
Filing Date
2024-06-28
Publication Date
2024-12-28

AI Technical Summary

Technical Problem

Existing single-agent or single-agent immune checkpoint inhibitors have insufficient targeting, low safety, inconvenient administration and high development costs when treating tumors, making it difficult to effectively inhibit immunosuppressive signals in the tumor microenvironment. , leading to poor treatment effect and drug resistance problems.

Method used

Develop bispecific antibodies targeting PD-L1 and IL-1, and bind antibodies or antigen-binding fragments to PD-L1 on the surface of tumor cells and IL-1R1 or IL-1β in the tumor microenvironment, to form Highly targeted, safe and low-development bispecific antibodies for the treatment of multiple types of tumors.

Benefits of technology

It significantly improves the killing effect of CD8+ T cells on tumors, inhibits tumor growth and migration, reduces immunosuppression, improves the efficacy and safety of treatment, and reduces tumor escape and drug resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025008327_DRAWING_001
    Figure PI2025008327_DRAWING_001
  • Figure PI2025008327_DRAWING_002
    Figure PI2025008327_DRAWING_002
  • Figure PI2025008327_DRAWING_003
    Figure PI2025008327_DRAWING_003
Patent Text Reader

Abstract

Provided is a bispecific antibody comprising a first moiety targeting PD-L1 and a second moiety targeting IL-1, wherein the first moiety comprises an anti-PD-L1 antibody or an antigen-binding fragment thereof, and the second moiety comprises an extracellular binding domain of an IL-1 receptor (IL-1R) or a variant thereof or an anti-IL-1β antibody or an antigen-binding fragment thereof. Further provided is the use of the bispecific antibody in the treatment of tumors. Figure 1A
Need to check novelty before this filing date? Find Prior Art

Description

Bispecific antibodies targeting PD-L1 and IL-1 and uses thereof Technical Field

[0001] The present invention relates to a bispecific antibody, in particular a bispecific antibody comprising a first portion targeting PD-L1 and a second portion targeting IL-1. The present invention also relates to the use of the bispecific antibody in treating tumors. Background Art

[0002] The mechanism of action is to simultaneously target PD-L1 on the surface of tumor cells and IL-1R1 or IL-1β in the tumor microenvironment, achieving better therapeutic effects than single drugs or combination of single drugs.

[0003] Studies have shown that PD-L1 is highly expressed on the surface of various tumor cells. When PD-L1 on the surface of tumor cells binds to PD-1 on the surface of T cells, it inhibits T cells from killing tumor cells and reduces CD8 + Antibodies targeting PD-L1 can inhibit the binding of PD-L1 to PD-1, restoring the anti-tumor effect of T cells and demonstrating significant efficacy in the treatment of patients with various tumor types, including malignant melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, and gastric cancer.

[0004] IL-1β is a member of the IL-1 cytokine family. After binding to IL-1R1, IL-1α or IL-1β forms a complex with the IL-1R accessory protein (IL-1RAcP). This complex activates IL-1R-associated kinase (IRAK), which in turn activates nuclear genes through NF-κB and other transcription factors. Studies have shown that IL-1β is upregulated in the tumor microenvironment (TME) of various cancers, including breast, gastric, pancreatic, and lung cancers. It can alter the composition of the TME by recruiting immunosuppressive cells such as MDSCs, tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), and Th17 cells, which are themselves sources of IL-1β. Furthermore, recent studies have shown that tumors themselves are a source of IL-1β, establishing a self-stimulatory cycle that sustains IL-1β synthesis and release. Tumor-derived IL-1β has also been shown to promote the expression of angiogenic factors such as VEGF. In summary, TME-derived IL-1β and tumor-derived IL-1β can not only promote tumor growth and migration, but also participate in the occurrence of tumor resistance by inducing anti-apoptotic signals. Antibodies targeting IL-1β have been shown to inhibit tumor growth and migration, increase CD8 + T cell infiltration into tumor tissue and reduction of immunosuppression.

[0005] The latest preclinical and clinical data show that combining immune checkpoint inhibitors with drugs that negatively regulate IL-1 signaling is a promising strategy for the treatment of solid tumors. Antibody fusion proteins or bispecific antibodies that simultaneously target PD-L1 and IL-1R1 or PD-L1 and IL-1β have advantages over single-drug combinations such as strong specificity and targeting, high safety, convenient administration and low development cost.

[0006] Summary of the Invention

[0007] In one aspect, provided herein is a bispecific antibody comprising a first portion that targets PD-L1 and a second portion that targets IL-1, wherein the first portion comprises an anti-PD-L1 antibody or an antigen-binding fragment thereof, the anti-PD-L1 antibody comprising HCDR1, HCDR2, and HCDR3 from the heavy chain variable region (VH) of SEQ ID NO: 17 and LCDR1, LCDR2, and LCDR3 from the light chain variable region (VL) of SEQ ID NO: 18.

[0008] In some embodiments, the anti-PD-L1 antibody comprises the sequence of SEQ ID NO: 17 or an amino acid sequence having at least 90% sequence identity thereto and the sequence of SEQ ID NO: 18 or an amino acid sequence having at least 90% sequence identity thereto.

[0009] In some embodiments, the heavy chain constant region of the anti-PD-L1 antibody is from IgG1, and the light chain constant region of the anti-PD-L1 antibody is from a kappa light chain.

[0010] In some embodiments, the second portion comprises the extracellular binding domain of the IL-1 receptor (IL-1R) or a variant thereof.

[0011] In some embodiments, the second portion comprises the sequence shown in SEQ ID NO: 14 or an amino acid sequence having at least 90% sequence identity thereto.

[0012] In some embodiments, there are two second portions, which are respectively connected to the N-terminus of the VH of the anti-PD-L1 antibody, the N-terminus of the VL of the anti-PD-L1 antibody, the C-terminus of the heavy chain constant region of the anti-PD-L1 antibody, or the C-terminus of the light chain constant region of the anti-PD-L1 antibody through the same or different linker sequences.

[0013] In some embodiments, the second portion is one, connected to the N-terminus of the VH of the anti-PD-L1 antibody, the N-terminus of the VL of the anti-PD-L1 antibody, the C-terminus of the heavy chain constant region of the anti-PD-L1 antibody, or the C-terminus of the light chain constant region of the anti-PD-L1 antibody via a linker sequence.

[0014] In some embodiments, the first portion is further connected to the Fab antigen-binding fragment of the anti-PD-L1 antibody at the C-terminus of the heavy chain constant region of the anti-PD-L1 antibody via a linker sequence.

[0015] In some embodiments, the second moiety is an anti-IL-1β antibody or an antigen-binding fragment thereof.

[0016] In some embodiments, the anti-IL-1β antibody comprises HCDR1, HCDR2, and HCDR3 from the VH set forth in SEQ ID NO: 15 and LCDR1, LCDR2, and LCDR3 from the VL set forth in SEQ ID NO: 16.

[0017] In some embodiments, the anti-IL-1β antibody comprises SEQ ID NO: 15 or an amino acid sequence having at least 90% sequence identity thereto and SEQ ID NO: 16 or an amino acid sequence having at least 90% sequence identity thereto.

[0018] In some embodiments, the heavy chain constant region of the anti-IL-1β antibody is from IgG1, and the light chain constant region of the anti-PD-L1 antibody is from a kappa light chain.

[0019] In some embodiments, the antigen-binding fragment of the anti-IL-1β antibody is in the form of Fab or scFv.

[0020] In some embodiments, the heavy chain constant region of the anti-PD-L1 antibody and / or the heavy chain constant region of the anti-IL-1β antibody are mutated to enable Knob-hole binding between the heavy chain constant regions.

[0021] In some embodiments, the first part and the second part are connected by the same or different linker sequences. Preferably, the linker sequence is selected from (G4S)4G, (G4S)3G, (G4S)4 and (G4S)3.

[0022] In some embodiments, the heavy chain of the anti-PD-L1 antibody comprises the sequence shown in SEQ ID NO: 9, or an amino acid sequence having at least 90% sequence identity thereto, and the light chain of the anti-PD-L1 antibody comprises the sequence shown in SEQ ID NO: 8, or an amino acid sequence having at least 90% sequence identity thereto.

[0023] In some embodiments, the heavy chain of the anti-IL-1β antibody comprises the sequence shown in SEQ ID NO: 7, or an amino acid sequence having at least 90% sequence identity thereto, and the light chain of the anti-IL-1β antibody comprises the sequence shown in SEQ ID NO: 6, or an amino acid sequence having at least 90% sequence identity thereto.

[0024] In some embodiments, the antigen-binding fragment of the anti-PD-L1 antibody in scFv format comprises the sequence shown in SEQ ID NO: 66 or an amino acid sequence having at least 90% sequence identity thereto.

[0025] In some embodiments, the antigen-binding fragment of the anti-IL-1β antibody in scFv format comprises the sequence of SEQ ID NO: 64 or 65, or an amino acid sequence having at least 90% sequence identity thereto.

[0026] In some embodiments, the bispecific antibody has any one of the schematic antibody structures in Figures 1A-1I.

[0027] In some embodiments, the bispecific antibody has any one of the schematic antibody structures in Figures 2A-2J.

[0028] In some embodiments, the extracellular binding domain of the IL-1 receptor (IL-1R) or a variant thereof is linked to an Fc fragment at its C-terminus.

[0029] In some embodiments, the heavy chain constant region and / or Fc fragment comprises an N297A mutation.

[0030] In some embodiments, the heavy chain constant region and / or Fc fragment are from human IgG1.

[0031] In some embodiments, the heavy chain constant region comprises the sequence shown in SEQ ID NO: 68, and the Fc fragment comprises the sequence shown in SEQ ID NO: 67.

[0032] In some embodiments, the second portion comprises the sequence shown in SEQ ID NO: 10 or 66.

[0033] In some embodiments, the bispecific antibody comprises a polypeptide chain listed in any row of Table 1.

[0034] In some embodiments, the bispecific antibody comprises:

[0035] 1) a polypeptide chain having a sequence represented by SEQ ID NO: 25 and a polypeptide chain having a sequence represented by SEQ ID NO: 26;

[0036] 2) a polypeptide chain having a sequence represented by SEQ ID NO: 25 and a polypeptide chain having a sequence represented by SEQ ID NO: 30;

[0037] 3) a polypeptide chain having a sequence represented by SEQ ID NO: 32 and a polypeptide chain having a sequence represented by SEQ ID NO: 28;

[0038] 4) a polypeptide chain having a sequence set forth in SEQ ID NO: 40, a polypeptide chain having a sequence set forth in SEQ ID NO: 39, and a polypeptide chain having a sequence set forth in SEQ ID NO: 28;

[0039] 5) a polypeptide chain having a sequence represented by SEQ ID NO: 43 and a polypeptide chain having a sequence represented by SEQ ID NO: 44;

[0040] 6) a polypeptide chain having a sequence represented by SEQ ID NO: 45 and a polypeptide chain having a sequence represented by SEQ ID NO: 46;

[0041] 7) a polypeptide chain having a sequence set forth in SEQ ID NO: 33, a polypeptide chain having a sequence set forth in SEQ ID NO: 28, a polypeptide chain having a sequence set forth in SEQ ID NO: 50, and a polypeptide chain having a sequence set forth in SEQ ID NO: 51;

[0042] 8) a polypeptide chain having a sequence represented by SEQ ID NO: 62 and a polypeptide chain having a sequence represented by SEQ ID NO: 63;

[0043] 9) a polypeptide chain having a sequence represented by SEQ ID NO: 69 and a polypeptide chain having a sequence represented by SEQ ID NO: 30;

[0044] 10) a polypeptide chain having a sequence represented by SEQ ID NO: 70 and a polypeptide chain having a sequence represented by SEQ ID NO: 28;

[0045] 11) a polypeptide chain having a sequence represented by SEQ ID NO: 71 and a polypeptide chain having a sequence represented by SEQ ID NO: 46; or

[0046] 12) The polypeptide chain of SEQ ID NO: 72 and the polypeptide chain of SEQ ID NO: 63.

[0047] In another aspect, provided herein are nucleic acid molecules encoding the aforementioned bispecific antibodies or polypeptide chains thereof.

[0048] In another aspect, provided herein is an expression vector comprising the above-described nucleic acid molecule.

[0049] In another aspect, provided herein is a pharmaceutical composition comprising:

[0050] 1) the aforementioned bispecific antibody, nucleic acid molecule, or expression vector; and

[0051] 2) Pharmaceutically acceptable carrier.

[0052] In another aspect, the present invention provides use of the aforementioned bispecific antibody, nucleic acid molecule, or expression vector in the preparation of a medicament for treating tumors.

[0053] In some embodiments, the tumor is selected from malignant melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, gastric cancer, breast cancer, pancreatic cancer, and lung cancer.

[0054] In another aspect, provided herein is a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of the aforementioned bispecific antibody, nucleic acid molecule, expression vector, or pharmaceutical composition.

[0055] In some embodiments, the tumor is selected from malignant melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, gastric cancer, breast cancer, pancreatic cancer, and lung cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figures 1A-1I are schematic diagrams of the structures of the bispecific antibodies of the present invention comprising Anakinra.

[0057] 2A-2J are schematic diagrams of the structures of bispecific antibodies of the present invention comprising an anti-IL-1β antibody or an antigen-binding fragment thereof.

[0058] Figures 3A-3H show the binding affinity results of the bispecific antibodies of the present invention to huPD-L1-His.

[0059] Figures 4A-4H show the binding affinity results of the bispecific antibodies of the present invention to huIL-1R1-His or IL-1β-His.

[0060] Figures 5A-5F show the results of the blocking effect of the bispecific antibodies of the present invention on IL-1β / IL-1R1 activity.

[0061] Figures 6A-6H show the binding affinity results of the bispecific antibodies of the present invention to huPD-L1-CHO-K cells.

[0062] Figures 7A-7I show the results of blocking the PD-1 / PD-L1 binding activity of the bispecific antibody of the present invention.

[0063] Figures 8A-8H show the results of the bispecific antibodies of the present invention blocking the PD-1 / PD-L1 signaling pathway.

[0064] Figures 9A-9H show the results of the ability of the bispecific antibodies of the present invention to simultaneously bind to huPD-L1 and IL-1R1 or IL-1β.

[0065] 10A-10I show the SDS-PAGE results of the bispecific antibody of the present invention and the reference substance IPI.

[0066] 11A-11AD show the SEC-HPLC results of the bispecific antibodies of the present invention. DETAILED DESCRIPTION

[0067] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0068] IL-1β and IL-1R1 are the most important inflammatory factors and their receptors in the tumor microenvironment. Blocking their signaling pathways has been shown to inhibit tumor growth and metastasis and help relieve immune checkpoint suppression in the tumor microenvironment. Combining immune checkpoint inhibitors with drugs that block the IL-1 signaling pathway is a novel and promising strategy for the treatment of solid tumors. Dual-targeting antibody fusion proteins or bispecific antibodies offer advantages over single-agent combinations, such as strong targeting, improved safety, convenient administration, and low development costs. They may also reduce tumor escape and overcome drug resistance.

[0069] The invention generally described herein will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended to limit the invention. The experimental methods in the following examples, for which no specific conditions are specified, were performed according to conventional methods and conditions, or according to commercial specifications.

[0070] Example 1 Preparation of raw materials

[0071] 1.1 Antigen preparation

[0072] The IL-1 used in the present invention is IL-1β, and the primary receptor used is IL-1R1. Human IgG1 Fc fragments (SEQ ID NO: 4) or 6×His tags (such as SEQ ID NO: 5) were fused to the C-termini of the human IL-1β extracellular region (UNIPROT: P01584, SEQ ID NO: 1), the human IL-1R1 extracellular region (UNIPROT: P14778, SEQ ID NO: 2), and the human PD-L1 extracellular region (UNIPROT: Q9NZQ7, SEQ ID NO: 3) to prepare huIL-1β-Fc, huIL-1β-His, huIL-1R1-Fc, huIL-1R1-His, huPD-L1-Fc, and huPD-L1-His antigen proteins. After the amino acid sequence was converted into a gene sequence, the target fragment gene was synthesized by General Biotechnology Co., Ltd., and each target fragment was amplified by PCR. Then, it was constructed into the pcDNA3.4 (Invitrogen) expression vector by homologous recombination. The constructed recombinant protein expression vectors were transformed into Escherichia coli SS320, cultured overnight at 37°C, and then the plasmids were extracted using an endotoxin-free plasmid extraction kit (OMEGA, D6950-01) to obtain endotoxin-free plasmids for eukaryotic expression. The obtained expression vectors were expressed using the Expi293 transient expression system (ThermoFisher, A14635). For transient transfection methods, see Expi293. TM Expression System USER GUIDE.

[0073] 5-7 days after transfection, the cell expression supernatant was purified according to different tags. For the His-tagged protein supernatant, Ni Smart Beads 6FF (Changzhou Tiandi Renhe Biotechnology Co., Ltd., SA036050) was used for affinity purification, and the target protein was eluted with gradient concentrations of imidazole. The eluted proteins were exchanged into buffer through ultrafiltration concentration tubes (Millipore, UFC901096), and after SDS-PAGE identification and activity identification, they were frozen at -80°C. For the Fc-tagged protein supernatant, after filtration through a 0.22μm filter membrane, affinity purification was performed using a Protein A / G affinity chromatography column. After purification, the target protein was eluted with 100mM glycine salt (pH 3.0), then concentrated and exchanged, and after SDS-PAGE identification and activity identification, they were frozen at -80°C.

[0074] 1.2 Preparation of positive control molecules

[0075] The positive control antibody for blocking IL-1 activity prepared in this example is Canakinumab, and the anti-PD-L1 positive control antibody is Atezolizumab (Atezolizumab, Genentech), which were synthesized according to the sequences disclosed in International Application WO2001053353A2 and U.S. Patent US8217149B (the light chain and heavy chain of Canakinumab are SEQ ID NO: 6 and SEQ ID NO: 7, respectively, and the light chain and heavy chain of Atezolizumab are SEQ ID NO: 8 and SEQ ID NO: 9, respectively). Plasmids containing the Canakinumab light chain gene, the Canakinumab heavy chain gene, the Atezolizumab light chain gene, and the Atezolizumab heavy chain gene were constructed by molecular cloning methods. The protein was expressed using the ExpiCHO transient transfection system, and the resulting supernatant was filtered through 0.22 μm and purified using the Protein A / G affinity purification method. Positive control antibodies Canakinumab and Atezolizumab were then eluted with 100 mM glycine (pH 3.0).

[0076] In this example, the positive control proteins Anakinra-Fc (SEQ ID NO: 10) and Anakinra-Fc (N297A) (SEQ ID NO: 66) were also prepared using the same method.

[0077] 1.3 Cell line construction

[0078] 1.3.1 Construction of huIL-1R1-HEK293 cell line

[0079] Construct a recombinant vector plasmid expressing the full length of human IL-1R1 (UniProtKB-P14778, SEQ ID NO: 11) and introduce the plasmid into HEK293 cells by electroporation A cell line expressing high expression of human IL-1R1 was screened and identified by flow cytometry (Beckman, CytoFLEX AOO-1-1102) using the positive control Anakinra-Fc or IL-1β-Fc, and was named Hu-IL-1R1-FL-HEK293 cells.

[0080] 1.3.2 Construction of IL-1R1-NF-κB-HEK293 cell line

[0081] Construct a recombinant vector plasmid expressing the full length of human IL-1R1 and a NF-κB luciferase reporter gene plasmid (which contains a luciferase reporter gene driven by the NF-κB response element), and use electroporation to co-introduce the above plasmids into HEK293 cells After selecting monoclonal cell lines using puromycin at a final concentration of 2 μg / mL, cell lines highly expressing human IL-1R1 were screened and identified by flow cytometry (Beckman, CytoFLEX AOO-1-1102) using the positive control Anakinra-Fc or IL-1β-Fc. Luciferase assay was performed to identify IL-1R1-NF-κB-HEK293 cells.

[0082] 1.3.3 Construction of huPD-L1-CHO-K cell line

[0083] The DNA fragment of human PD-L1 full length (UniProtKB-Q9NZQ7, SEQ ID NO: 12) was synthesized by gene synthesis technology and cloned into the expression vector. It was introduced into E. coli by chemical transformation. The E. coli single clone was picked and sequenced to obtain the correct plasmid clone. The plasmid was extracted and sequenced again for confirmation. CHO-K (Thermo, A1461801) cells were cultured using CD-CHO serum-free medium (Gibco, 10743029). The cells were passaged to 5×10 6 The next day, the constructed plasmid was introduced into CHO-K cells using an Invitrogen electroporation kit (Cat. No. MPK10096) and electroporator (Cat. No. MP922947). The electroporated cells were transferred to CD-CHO medium and cultured in a 37°C cell culture incubator for 48 hours. The electroporated CHO-K cells were plated at 2,000 cells / well in a 96-well plate and supplemented with 30 μM MSX (Millipore, GSS-1015-F) and GS supplement (Sigma, 58672C-100ml) at a final concentration. The cells were then cultured in a 37°C CO2 incubator. After 10 days, medium containing 30 μM MSX and 1× GS supplement was added. Single cell clones that emerged from the 96-well plate were picked and transferred to 24-well plates for further expansion. Stable huPD-L1-CHO-K cell lines were successfully isolated by FACS analysis.

[0084] 1.3.4 Construction of CD3L-PD-L1-CHO cell line

[0085] The CD3L-PD-L1-CHO cell line was constructed based on a CHO cell line (CD3L-CHO cells) that the applicant had prepared that stably expressed CD3L (a membrane-anchored anti-CD3-scFv that can directly stimulate CD3 signal transduction). Specifically, a plasmid expressing the full-length human PD-L1 was introduced into the CD3L-CHO cells using electroporation; monoclonal cell lines were selected using antibiotics; and finally, cell lines stably expressing human PD-L1 were identified by FACS and named CD3L-PD-L1-CHO cell line.

[0086] 1.3.5 Construction of Jurkat-PD-1-NFAT cell line

[0087] The Jurkat-PD-1-NFAT cell line was constructed based on a Jurkat cell line (Jurkat-NFAT cells) stably transfected with a NFAT luciferase reporter gene plasmid (which contains a luciferase reporter gene driven by an NFAT response element) prepared by the applicant. Specifically, a plasmid expressing the full-length human PD-1 (UNIPROT: Q15116, SEQ ID NO: 13) was introduced into Jurkat-NFAT cells by electroporation; monoclonal cell lines were selected using puromycin at a final concentration of 2 μg / mL; and cell lines stably expressing human PD-1 were identified by FACS and named Jurkat-PD-1-NFAT cell line.

[0088] Example 2: Design and Construction of Anti-PD-L1 and IL-1 Bispecific Antibody

[0089] This example describes the construction of exemplary anti-PD-L1 and IL-1 blocking bispecific antibodies and expression vectors. Twenty-four constructs were designed: antagonist protein amino acid sequences derived from the antagonist protein Anakinra (SEQ ID NO: 14), anti-IL-1 antibody amino acid sequences derived from the anti-IL-1β antibody Canakinumab (VH and VL SEQ ID NO: 15 and SEQ ID NO: 16, respectively), and anti-PD-L1 antibody amino acid sequences derived from Atezolizumab (VH and VL SEQ ID NO: 17 and SEQ ID NO: 18, respectively); in some constructs, the linker amino acid sequences were (G4S)3G (SEQ ID NO: 19), (G4S)4G (SEQ ID NO: 20), (G4S)3 (SEQ ID NO: 21), (G4S)4 (SEQ ID NO: 22), TVAAPSVFIFPP (SEQ ID NO: 23), or ASTKGPSVFPLAP (SEQ ID NO: 24). The antibody configurations are shown in Figures 1A-1I and 2A-2J, and the corresponding amino acid sequences are shown in Table 1. The specific antibody configurations are as follows:

[0090] Construct BsAb1: Contains two identical first polypeptide chains, comprising, from N-terminus to C-terminus, the VH domain of the anti-PD-L1 antibody atezolizumab and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, IgG1 heavy chain hinge region, and IgG1 heavy chain Fc); contains two identical second polypeptide chains, comprising, from N-terminus to C-terminus, the IL-1R1 antagonist protein Anakinra, a linker (G4S)4G, the VL domain of atezolizumab, and the antibody kappa light chain CL domain. BsAb1 has the format of Figure 1A.

[0091] Construct BsAb2: Contains two identical first polypeptide chains, comprising, from N-terminus to C-terminus, Anakinra, a linker (G4S)4G, the VH domain of atezolizumab, and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, IgG1 heavy chain hinge region, and IgG1 heavy chain Fc); and two identical second polypeptide chains, comprising, from N-terminus to C-terminus, the VL domain of atezolizumab and the antibody kappa light chain CL domain. Construct BsAb3 differs from construct BsAb2 in the linker in the first polypeptide chain; BsAb3's linker is (G4S)3G. BsAb2 and BsAb3 have the format shown in Figure 1B.

[0092] Construct BsAb4: Contains two identical first polypeptide chains, comprising, from N-terminus to C-terminus, the VH domain of atezolizumab and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, IgG1 heavy chain hinge region, and IgG1 heavy chain Fc); and two identical second polypeptide chains, comprising, from N-terminus to C-terminus, the VL domain of atezolizumab, the antibody kappa light chain CL domain, a linker (G4S)4G, and Anakinra. BsAb4 has the format of Figure 1C.

[0093] Construct BsAb5: Contains two identical first polypeptide chains, comprising, from N-terminus to C-terminus, the atezolizumab VH domain, the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, IgG1 heavy chain hinge region, and IgG1 heavy chain Fc), a linker (G4S)4G, and Anakinra; and contains two identical second polypeptide chains, comprising, from N-terminus to C-terminus, the atezolizumab VL domain and the antibody kappa light chain CL domain. Constructs BsAb6 and BsAb5 differ in the linker in the first polypeptide chain; BsAb6's linker is (G4S)3G. BsAb5 and BsAb6 have the format shown in Figure 1D.

[0094] Construct BsAb7: Contains three polypeptide chains. The first polypeptide chain contains the VH domain of atezolizumab and the IgG1 heavy chain constant region domain (including IgG1 heavy chain CH1, IgG1 heavy chain hinge region and IgG1 heavy chain Knob mutant Fc) from the N-terminus to the C-terminus; the second polypeptide chain contains Anakinra, a linker (G4S )4 G, the VH domain of atezolizumab, the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain hole mutant Fc); two identical third polypeptide chains, from N-terminus to C-terminus, comprising the VL domain of atezolizumab and the antibody kappa light chain CL domain. BsAb7 has the format of Figure 1E.

[0095] Construct BsAb8: Contains 4 polypeptide chains. The first polypeptide chain contains the VH domain of atezolizumab and the IgG1 heavy chain constant region domain (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain knob mutant Fc) from the N-terminus to the C-terminus; the second polypeptide chain contains the VL domain of atezolizumab and the antibody kappa light chain CL domain from the N-terminus to the C-terminus; the third polypeptide chain contains the VH domain of atezolizumab, the antibody kappa light chain CL domain, and the IgG1 heavy chain hole mutant Fc from the N-terminus to the C-terminus; the fourth polypeptide chain contains Anakinra, a linker (G4S )4 G, VL domain of atezolizumab, antibody IgG1 heavy chain CH1 and IgG1 heavy chain hinge region (EPKSC). BsAb8 has the format of Figure 1F.

[0096] Construct BsAb9: Contains four polypeptide chains. The first polypeptide chain, from N-terminus to C-terminus, contains the atezolizumab VH domain and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain knob mutant Fc); the second polypeptide chain, from N-terminus to C-terminus, contains the atezolizumab VL domain and the antibody kappa light chain CL domain; the third polypeptide chain, from N-terminus to C-terminus, contains the atezolizumab VL domain and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain hole mutant Fc); and the fourth polypeptide chain, from N-terminus to C-terminus, contains the atezolizumab VH domain, the antibody kappa light chain CL domain, the linker (G4S)4G, and Anakinra. BsAb9 has the format shown in Figure 1G.

[0097] Construct BsAb10: Contains three polypeptide chains. The first polypeptide chain, from N-terminus to C-terminus, contains the atezolizumab VH domain and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain knob mutant Fc). The second polypeptide chain, from N-terminus to C-terminus, contains the atezolizumab VH domain, the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain hole mutant Fc), a linker (G4S)4G, and Anakinra. Two identical third polypeptide chains, from N-terminus to C-terminus, contain the atezolizumab VL domain and the antibody kappa light chain CL domain. BsAb10 has the format shown in Figure 1H.

[0098] Construct BsAb11 comprises three polypeptide chains. The first polypeptide chain, from N-terminus to C-terminus, comprises the atezolizumab VH domain, the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain knob mutant Fc), a linker (G4S)3, the atezolizumab VH domain, the IgG1 heavy chain CH1, and the IgG1 heavy chain hinge region (EPKSC). The second polypeptide chain, from N-terminus to C-terminus, comprises the atezolizumab VH domain, the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain hole mutant Fc), a linker (G4S)4G, and Anakinra. Three identical third polypeptide chains, from N-terminus to C-terminus, comprise the atezolizumab VL domain and the antibody kappa light chain CL domain. BsAb11 has the format of Figure 1I.

[0099] Construct BsAb12: Contains two identical first polypeptide chains, comprising, from N-terminus to C-terminus, the VH domain of canakinumab, a linker (G4S)3, the VH domain of atezolizumab, and an IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, IgG1 heavy chain hinge region, and IgG1 heavy chain Fc); and two identical second polypeptide chains, comprising, from N-terminus to C-terminus, the VL domain of canakinumab, a linker (G4S)3, the VL domain of atezolizumab, and an antibody kappa light chain CL domain. Construct BsAb13 differs from construct BsAb12 in that the linkers in the first and second polypeptide chains are different: the linker in the first polypeptide chain of construct BsAb13 is ASTKGPSVFPLAP, and the linker in the second polypeptide chain is TVAAPSVFIFPP. BsAb12 and BsAb13 have the format of Figure 2A.

[0100] Construct BsAb14: Contains two identical first polypeptide chains, comprising, from N-terminus to C-terminus, the VH domain of atezolizumab, a linker (G4S)3, the VH domain of canakinumab, and an IgG1 heavy chain constant region (including an IgG1 heavy chain CH1, an IgG1 heavy chain hinge region, and an IgG1 heavy chain Fc); and two identical second polypeptide chains, comprising, from N-terminus to C-terminus, the VL domain of atezolizumab, a linker (G4S)3, the VL domain of canakinumab, and an antibody kappa light chain CL domain. BsAb14 has the format of Figure 2A.

[0101] Construct BsAb15: Contains two identical first polypeptide chains, comprising, from N-terminus to C-terminus, the atezolizumab VH domain, the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain Fc), a linker (G4S)3, and the canakinumab scFv (VH-(G4S)3-VL); and two identical second polypeptide chains, comprising, from N-terminus to C-terminus, the atezolizumab VL domain and the antibody kappa light chain CL domain. BsAb15 has the format of Figure 2B.

[0102] Construct BsAb16: Contains four polypeptide chains. The first polypeptide chain comprises the atezolizumab VH domain and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, IgG1 heavy chain hinge region, and IgG1 heavy chain knob mutant Fc) from the N-terminus to the C-terminus; the second polypeptide chain comprises the atezolizumab VL domain and the antibody kappa light chain CL domain from the N-terminus to the C-terminus; the third polypeptide chain comprises the canakinumab VL domain, the antibody kappa light chain CL domain, and the IgG1 heavy chain hole mutant Fc from the N-terminus to the C-terminus; and the fourth polypeptide chain comprises the canakinumab VH domain, IgG1 heavy chain CH1, and IgG1 heavy chain hinge region (EPKSC) from the N-terminus to the C-terminus. BsAb16 has the format of Figure 2C.

[0103] Construct BsAb17: Contains four polypeptide chains. The first polypeptide chain, from N-terminus to C-terminus, comprises the VH domain of atezolizumab and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, IgG1 heavy chain hinge region, and IgG1 heavy chain knob mutant Fc); the second polypeptide chain, from N-terminus to C-terminus, comprises the VL domain of atezolizumab and the antibody kappa light chain CL domain; the third polypeptide chain, from N-terminus to C-terminus, comprises the VH domain of canakinumab, the antibody kappa light chain CL domain, and the IgG1 heavy chain hole mutant Fc; and the fourth polypeptide chain, from N-terminus to C-terminus, comprises the VL domain of canakinumab, the IgG1 heavy chain CH1, and the IgG1 heavy chain hinge region (EPKSC). BsAb17 has the format shown in Figure 2D.

[0104] Construct BsAb18: Contains four polypeptide chains. The first polypeptide chain comprises, from N-terminus to C-terminus, the VH domain of atezolizumab and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain knob mutant Fc); the second polypeptide chain comprises, from N-terminus to C-terminus, the VL domain of atezolizumab and the antibody kappa light chain CL domain; the third polypeptide chain comprises, from N-terminus to C-terminus, the VL domain of canakinumab and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain hole mutant Fc); and the fourth polypeptide chain comprises, from N-terminus to C-terminus, the VH domain of canakinumab and the antibody kappa light chain CL domain. BsAb18 has the format shown in Figure 2E.

[0105] Construct BsAb19: Contains three polypeptide chains. The first polypeptide chain, from N-terminus to C-terminus, comprises the VH domain of atezolizumab, the IgG1 heavy chain constant region domain (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain knob mutant Fc), the linker (G4S)3, and the canakinumab scFv (VH-(G4S)3-VL). The second polypeptide chain, from N-terminus to C-terminus, comprises the VH domain of atezolizumab and the IgG1 heavy chain constant region domain (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain hole mutant Fc). Two identical third polypeptide chains, from N-terminus to C-terminus, comprise the VL domain of atezolizumab and the antibody kappa light chain CL domain. BsAb19 has the format shown in Figure 2F.

[0106] Construct BsAb20: Contains three polypeptide chains. The first polypeptide chain, from N-terminus to C-terminus, comprises the atezolizumab VH domain and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, IgG1 heavy chain hinge region, and IgG1 heavy chain knob mutant Fc); the second polypeptide chain, from N-terminus to C-terminus, comprises the canakinumab scFv (VH-(G4S)3-VL), the linker (G4S)3, the IgG1 heavy chain hinge region, and the IgG1 heavy chain hole mutant Fc; the third polypeptide chain, from N-terminus to C-terminus, comprises the atezolizumab VL domain and the antibody kappa light chain CL domain. BsAb20 has the format shown in Figure 2G.

[0107] Construct BsAb21: Contains three polypeptide chains. The first polypeptide chain, from N-terminus to C-terminus, comprises the atezolizumab VH domain, the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain knob mutant Fc), the atezolizumab VH domain, the IgG1 heavy chain CH1, and the IgG1 heavy chain hinge region (EPKSC). The second polypeptide chain, from N-terminus to C-terminus, comprises the atezolizumab VH domain, the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, the IgG1 heavy chain hinge region, and the IgG1 heavy chain hole mutant Fc), the linker (G4S)3, and the canakinumab scFv (VH-(G4S)3-VL). Three identical third polypeptide chains, from N-terminus to C-terminus, comprise the atezolizumab VL domain and the antibody kappa light chain CL domain. BsAb21 has the format shown in Figure 2H.

[0108] Construct BsAb22: Contains four polypeptide chains. The first polypeptide chain, from N-terminus to C-terminus, comprises the VH domain of atezolizumab and the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, IgG1 heavy chain hinge region, and IgG1 heavy chain F405L mutant Fc); the second polypeptide chain, from N-terminus to C-terminus, comprises the VL domain of atezolizumab and the antibody kappa light chain CL domain; the third polypeptide chain, from N-terminus to C-terminus, comprises the VH domain of canakinumab, the antibody kappa light chain CL domain, and the IgG1 heavy chain K409R mutant Fc; and the fourth polypeptide chain, from N-terminus to C-terminus, comprises the VL domain of canakinumab, the IgG1 heavy chain CH1, and the IgG1 heavy chain hinge region (EPKSC). BsAb22 has the format of Figure 2I.

[0109] Construct BsAb23: Contains two identical first polypeptide chains, comprising, from N-terminus to C-terminus, the atezolizumab VH domain, the IgG1 heavy chain constant region (including the IgG1 heavy chain CH1, IgG1 heavy chain hinge region, and IgG1 heavy chain Fc), a linker (G4S)4, and the canakinumab scFv (VH-(G4S)4-VL); and two identical second polypeptide chains, comprising, from N-terminus to C-terminus, the atezolizumab VL domain and the antibody kappa light chain CL domain. BsAb23 has the format shown in Figure 2J.

[0110] Construct BsAb25: Contains two identical first polypeptide chains, comprising, from N-terminus to C-terminus, the VH domain of canakinumab, an IgG1 heavy chain constant region (including IgG1 heavy chain CH1, IgG1 heavy chain hinge region, IgG1 heavy chain Fc), a linker (G4S)4, and atezolizumab scFv (VH(G44C mutation)-(G4S)4-VL(Q100C mutation)); and two identical second polypeptide chains, comprising, from N-terminus to C-terminus, the VL domain of canakinumab and an antibody kappa light chain CL domain. BsAb25 has the format of Figure 2J .

[0111] Construct BsAb26: Contains two identical first polypeptide chains, comprising the VH domain of atezolizumab and the human IgG1 heavy chain constant region domain (including human IgG1 heavy chain CH1, human IgG1 heavy chain hinge region and human IgG1 heavy chain Fc (N297A) from N-terminus to C-terminus; contains two identical second polypeptide chains, comprising the VL domain of atezolizumab, the antibody kappa light chain CL domain, the linker (G4S)4G and Anakinra from N-terminus to C-terminus. BsAb26 has the format of Figure 1C.

[0112] Construct BsAb27: Contains two identical first polypeptide chains, comprising the VH domain of atezolizumab, a human IgG1 heavy chain constant region domain (including human IgG1 heavy chain CH1, human IgG1 heavy chain hinge region and human IgG1 heavy chain Fc (N297A) from N-terminus to C-terminus, a linker of (G4S)3G and Anakinra; contains two identical second polypeptide chains, comprising the VL domain of atezolizumab and an antibody kappa light chain CL domain from N-terminus to C-terminus. BsAb27 has the format of Figure 1D.

[0113] Construct BsAb28: Contains two identical first polypeptide chains, comprising, from N-terminus to C-terminus, the VH domain of atezolizumab, a linker (G4S) 3, the VH domain of canakinumab, and a human IgG1 heavy chain constant region (including a human IgG1 heavy chain CH1, a human IgG1 heavy chain hinge region, and a human IgG1 heavy chain Fc (N297A)); and two identical second polypeptide chains, comprising, from N-terminus to C-terminus, the VL domain of atezolizumab, a linker (G4S) 3, the VL domain of canakinumab, and an antibody kappa light chain CL domain. BsAb28 has the format of Figure 2A.

[0114] Construct BsAb29: Contains two identical first polypeptide chains, comprising the VH domain of Canakinumab, human IgG1 heavy chain constant region domain (including human IgG1 heavy chain CH1, human IgG1 heavy chain hinge region, human IgG1 heavy chain Fc (N297A)), linker (G4S) 4, and Atezolizumab scFv (VH (G44C mutation) - (G4S) 4 - VL (Q100C mutation)) from N-terminus to C-terminus; contains two identical second polypeptide chains, comprising the VL domain of Canakinumab and the antibody kappa light chain CL domain from N-terminus to C-terminus. BsAb29 has the form of Figure 2J

[0115] Based on the structure of the construct, individual fragments were amplified by PCR, linked by overlap extension PCR, and then constructed into the modified eukaryotic expression vector plasmid pcDNA3.3-TOPO (Invitrogen) via homologous recombination to form the complete full-length construct polypeptide chain gene. The constructed vectors containing the full-length construct polypeptide chain gene were transformed into Escherichia coli SS320 and cultured overnight at 37°C. Plasmid extraction was performed using an endotoxin-free plasmid extraction kit (OMEGA, D6950-01) to obtain endotoxin-free construct polypeptide chain plasmids for eukaryotic expression.

[0116] Table 1 Polypeptide chain amino acid sequences of anti-PD-L1 and IL-1 bispecific antibodies (SEQ ID NO)

[0117] Example 3 Expression, purification, and physicochemical property analysis of anti-PD-L1 and anti-IL-1 bispecific antibodies

[0118] 3.1 Expression and Purification of Anti-PD-L1 and Anti-IL-1 Bispecific Antibodies

[0119] The antibody of Example 2 was expressed using the ExpiCHO transient expression system (Thermo Fisher, A29133). The specific method was as follows: on the day of transfection, the CHO cell density was confirmed to be 7×10 6 -1×10 7 Cells were grown at a concentration of about 6 × 10 cells / mL and the cell viability was >98%. Fresh ExpiCHO expression medium pre-warmed at 37°C was used to adjust the cells to a final concentration of 6 × 10 6 / mL. Dilute the target plasmid with 4°C pre-cooled OptiPROTM SFM (add 1μg of plasmid to 1mL of the culture medium). At the same time, dilute ExpiFectamineTM CHO with OptiPROTM SFM, then mix equal volumes of the two and gently pipette to mix to prepare the ExpiFectamineTM CHO / plasmid DNA mixture. Incubate at room temperature for 1-5 minutes, slowly add to the prepared cell suspension while gently shaking, and finally place in a cell culture shaker and culture at 37°C and 8% CO2. 18-22h after transfection, add ExpiCHOTM Enhancer and ExpiCHOTM Feed to the culture medium, and continue to culture in a shaker at 32°C and 5% CO2. On the 5th day after transfection, add the same volume of ExpiCHOTM Feed and gently mix the cell suspension while slowly adding it. 7-15 days after transfection, the cell culture supernatant expressing the target protein was centrifuged at 15,000 g for 10 min. The resulting supernatant was affinity purified using MabSelect SuRe LX (GE, 17547403), and the target protein was eluted with 100 mM sodium acetate (pH 3.0), followed by neutralization with 1 M Tris-HCl, and finally the resulting protein was exchanged into PBS buffer using an ultrafiltration concentrator tube (Millipore, UFC901096).

[0120] 3.2 Concentration Determination of Anti-PD-L1 and Anti-IL-1 Bispecific Antibodies

[0121] The purified bispecific antibody of Example 3.1 was measured for concentration using an ultramicro spectrophotometer (Hangzhou Aosheng Instrument Co., Ltd., Nano-300). The measured A280 value was divided by the theoretical extinction coefficient of the antibody and used as the antibody concentration for subsequent studies. After passing quality inspection, the antibody was aliquoted and stored at -80°C.

[0122] 3.3 SDS-PAGE analysis of anti-PD-L1 and anti-IL-1 bispecific antibodies

[0123] Preparation of non-reducing solution: 1 μg of candidate antibody and reference substance IPI were added to 5× SDS loading buffer and 40 mM iodoacetamide, heated in a 75°C dry bath for 10 min, cooled to room temperature, centrifuged at 12,000 rpm for 5 min, and the supernatant was collected.

[0124] Preparation of reducing solution: 2 μg of candidate antibody and reference substance IPI were added to 5× SDS loading buffer and 5 mM DTT, heated in a dry bath at 100°C for 10 min, cooled to room temperature, centrifuged at 12,000 rpm for 5 min, and the supernatant was collected.

[0125] The supernatant was added to a Bis-tris 4-15% gradient gel (purchased from GenScript), and gel electrophoresis was performed at a constant voltage of 110 V and the protein bands were visualized by Coomassie Brilliant Blue staining. The protein gel was destained and scanned with an EPSON V550 color scanner. The purity of the reduced and non-reduced bands was calculated using ImageJ according to the peak area normalization method. The results are shown in Table 2 and Figures 10A-10I. The bands of the candidate bispecific antibodies and the reference product IPI non-reduced gel were all of the expected size, and the purity of BsAb12, BsAb13, BsAb14, BsAb16, BsAb22, BsAb25, BsAb28, and BsAb29 exceeded 95%.

[0126] 3.4 SEC-HPLC Assay of Anti-PD-L1 and Anti-IL-1 Bispecific Antibodies

[0127] Material preparation: 1. Mobile phase: 150 mmol / L phosphate buffer, pH 7.4; 2. Sample preparation: Dilute each antibody and quality control product IPI to 0.5 mg / mL with mobile phase solution.

[0128] An Agilent HPLC 1100 or Shimadzu LC2030C PLUS liquid chromatograph was used, with an XBridge BEH column (SEC 3.5 μm, 7.8 mm ID × 30 cm), a Waters flow rate of 0.8 mL / min, an injection volume of 20 μL, and a VWD detector wavelength of 280 nm and 214 nm. A blank solution, an IPI quality control solution, and an antibody sample solution were injected sequentially. The percentages of high-molecular-weight polymers, antibody monomers, and low-molecular-weight substances in the samples were calculated using the area normalization method. The results showed that the monomer purity of BsAb6, BsAb11, BsAb14, BsAb25, BsAb26, BsAb28, and BsAb29 was greater than 90% (Table 2 and Figures 11A-11AD).

[0129] Table 2 Preparation, physicochemical and purity data of anti-PD-L1 and IL-1 bispecific antibodies

[0130] Example 4 Evaluation of Antigen Binding and Blocking Activity of Anti-PD-L1 and Anti-IL-1 Bispecific Antibodies at the Protein Level

[0131] 5.1 Binding activity of candidate bispecific antibodies at the protein level

[0132] This example evaluates the antigen binding ability of candidate bispecific antibody molecules to PD-L1 or IL-1. The specific experimental method is as follows:

[0133] Human recombinant proteins huPD-L1-His, huIL-1R1-His or huIL-1β-His were coated on a 96-well ELISA plate at 4°C overnight. The next day, the plate was washed three times with PBST and blocked with 5% skim milk for 2 hours; after washing the plate three times with PBST, different concentrations of the test antibody were added and incubated for 1 hour. After that, the secondary antibody Anti-human-IgG-Fc-HRP (abcam, ab79225) was added and incubated for 1 hour after washing three times with PBST. After incubation, the plate was washed six times with PBST and TMB (SurModics, TMBS-1000-01) was added for color development. According to the color development results, 2M HCl was added to terminate the reaction, and the OD450 value was read using an enzyme reader (Molecular Devices, SpecterMax 190). Using PRISM TM Data were analyzed by GraphPad Software, San Diego, CA, and EC was calculated. 50 Value (nM).

[0134] The binding ability of the candidate bispecific antibodies to huPD-L1-His is shown in Figures 3A-3H. Each candidate molecule binds to the antigen PD-L1 with high affinity. Among them, BsAb4, BsAb6, BsAb26, BsAb27, and BsAb28 have the strongest binding, which is comparable to the positive control antibody Atezolizumab, while the others are weaker than the positive control antibody. In addition, as shown in Figures 4A-4H, the candidate bispecific antibody molecules have certain binding ability to huIL-1R1-His or IL-1β-His. Among them, BsAb12, BsAb13, and BsAb26 have the strongest binding, which is comparable to the positive control Canakinumab, while the others are weaker than the positive control Anakinra-Fc, Canakinumab, or Anakinra-Fc(N297A).

[0135] 5.2 Candidate bispecific antibody molecules block IL-1β / IL-1R1 binding activity

[0136] The obtained bispecific antibody was evaluated for its IL-1β / IL-1R1 blocking activity. An ELISA assay was used to determine whether the bispecific antibody blocked the binding of huIL-1β to huIL-1R1. The specific method is as follows:

[0137] The human recombinant protein huIL-1R1-Fc was coated on a 96-well ELISA plate at 4°C overnight. The next day, the plate was washed three times with PBST and blocked with 5% skim milk at room temperature for 2 hours; after washing the plate three times with PBST, different concentrations of the test antibody were added and incubated at room temperature for 1 hour. After washing three times with PBST, huIL-1β-His was added to the 96-well ELISA plate and incubated at room temperature for 1 hour. After that, the secondary antibody Anti-6*His-HRP (proteintech, HRP-66005) was added after washing three times with PBST and incubated at room temperature for 50 minutes. After incubation, the plate was washed six times with PBST and TMB (SurModics, TMBS-1000-01) was added for color development. According to the color development results, 2M HCl was added to terminate the reaction, and the OD450 value was read using an enzyme reader (Molecular Devices, SpecterMax 190). Using PRISM TM Data were analyzed by GraphPad Software (San Diego, CA), and IC was calculated. 50 Value (nM).

[0138] The blocking activity of the candidate bispecific antibodies against IL-1β / IL-1R1 is shown in Figures 5A-5F. The candidate molecules all have IL-1β / IL-1R1 blocking activity at the protein level, but are weaker than the positive controls Anakinra-Fc or Canakinumab.

[0139] Example 6 Evaluation of the Binding and Blocking Activity of Anti-PD-L1 and Anti-IL-1 Bispecific Antibodies in huPD-L1-CHO-K Cells

[0140] 6.1 Evaluation of Binding Activity of Candidate Bispecific Antibodies in huPD-L1-CHO-K Cells

[0141] The binding of the bispecific antibody to huPD-L1-CHO-K cells was detected by FACS (expressed as mean fluorescence intensity (MFI). The specific experimental method is as follows:

[0142] The huPD-L1-CHO-K cells in good culture were collected and centrifuged at 300 g to remove the supernatant. The cells were resuspended in FACS buffer (PBS buffer supplemented with 2% FBS), counted, and the cell suspension density was adjusted. 1×10 5Cells were centrifuged and the supernatant removed. Serial dilutions of the test antibody and the control antibody, atezolizumab, were then added to the corresponding wells. After incubation at 4°C for 60 minutes, the cells were rinsed three times with FACS buffer. 0.5 μg of PE-labeled goat anti-human IgG Fc antibody (Abcam, ab98596) was added and incubated at 4°C for 30 minutes. Finally, the cells were washed three times and resuspended in 200 μL of FACS buffer for analysis using a flow cytometer (Beckman, CytoFLEX AOO-1-1102).

[0143] The results are shown in Figures 6A-6H. The bispecific antibodies all bound to huPD-L1-CHO-K overexpressing cells with high affinity. Among them, the binding activity of BsAb4 and BsAb6 was significantly stronger than that of other candidate antibodies and the positive control antibody Atezolizumab, and the binding activity of BsAb5, BsAb10, BsAb11, BsAb14, BsAb19 and BsAb23 was comparable to that of the positive control antibody Atezolizumab.

[0144] 6.2 Evaluation of the blocking activity of candidate bispecific antibodies against PD-1 / PD-L1 at the cellular level

[0145] The FACS method was used to evaluate the activity of the bispecific antibody in blocking PD-1 / PD-L1 binding at the cellular level (expressed as mean fluorescence intensity (MFI)). The specific test method is as follows:

[0146] The huPD-L1-CHO-K cells in good culture were collected and centrifuged at 300 g to remove the supernatant. The cells were resuspended in FACS buffer (PBS buffer supplemented with 2% FBS), counted, and the cell suspension density was adjusted. 1×10 5 The cells were centrifuged and the supernatant was removed. Then, serial dilutions of the test antibody and the control antibody Atezolizumab were added to the corresponding wells and incubated at 4°C for 60 minutes. After washing the cells twice with FACS buffer, biotin-labeled PD-1-biotin protein was added and incubated at 4°C for 60 minutes. After that, the cells were washed twice with FACS buffer, PE-labeled streptavidin (Invitrogen, 12-4317-087) was added, and incubated at 4°C for 30 minutes. After the incubated cell mixture was washed three times, 200 μL of FACS buffer was added to resuspend the cells, and finally detected by flow cytometry (Beckman, CytoFLEX AOO-1-1102). The data were analyzed using PRISMTM (GraphPad Software, San Diego, CA), and the IC50 value was calculated.

[0147] As shown in Figures 7A-7I, most bispecific antibodies demonstrated comparable blocking activity against PD-1 / PD-L1 as the control antibody atezolizumab. Among them, BsAb4, BsAb6, BsAb11, and BsAb25 demonstrated significantly stronger blocking activity than the other candidate antibodies and the positive control antibody atezolizumab.

[0148] Example 7 Verification of the Blocking Activity of Anti-PD-L1 and IL-1 Bispecific Antibodies on the PD-1 / PD-L1 Signaling Pathway

[0149] The blocking activity of the bispecific antibody on the PD-1 / PD-L1 signaling pathway was evaluated using luciferase reporter gene assay.

[0150] Specific experimental method: First, culture and collect CD3L-huPD-L1-CHO-K and huPD-1-NF-AT-Jurkat cells with good growth status. Then, gradient dilution of the test double antibody and positive control Atezolizumab was added to a 96-well cell culture plate. The two cells were washed and resuspended in RPMI 1640 medium, and added at a ratio of 5:1 (1×10 huPD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells, respectively). 5 and 2×10 4 Cells were plated in a 96-well cell culture plate containing the test antibody (cells / well) and incubated in a 37°C cell culture incubator for 6 hours. After incubation, 50 μL of luciferase substrate Bright-Lite (Vazyme, DD1204-03) was added to each well and the fluorescence intensity was measured after shaking for 60 seconds.

[0151] The results are shown in Figures 8A-8H. Most bispecific antibodies showed strong activity in activating luciferase signals. Among them, BsAb4, BsAb6, BsAb11 and BsAb26 had better activation effects than the positive control antibody Atezolizumab, indicating that they have good blocking activity and immune activation activity on the PD-1 / PD-L1 signaling pathway.

[0152] Example 8: Steric hindrance analysis of preferred bispecific antibodies binding to dual antigen targets at the protein level

[0153] This example evaluates the ability of a preferred bispecific antibody molecule to simultaneously bind to PD-L1 and IL-1 antigens. The specific experimental method is as follows:

[0154] 96-well ELISA plates were coated with the human recombinant proteins huPD-L1-Fc, huIL-1R1-Fc, or huIL-1β-Fc at 4°C overnight. The next day, the plates were washed three times with PBST and blocked with 5% skim milk for 2 hours at room temperature. After washing three times with PBST, the plates were incubated with various concentrations of the test antibody for 1 hour. After washing three times with PBST, the plates were then incubated with the other antigens, huIL-1R1-His, huIL-1β-His, or huPD-L1-His, for 1 hour at room temperature. Following this, the plates were washed three times with PBST, and the secondary antibody, Anti-6*His-HRP (Proteintech; HRP-66005), was added and incubated at room temperature for 50 minutes. After incubation, the plates were washed six times with PBST and developed with TMB (SurModics, TMBS-1000-01). According to the color development results, 2M HCl was added to terminate the reaction, and the OD450 value was read using a microplate reader (Molecular Devices, SpecterMax 190). TM Data were analyzed by GraphPad Software, San Diego, CA, and EC was calculated. 50 Value (nM).

[0155] The ability of the preferred bispecific antibody to simultaneously bind to huPD-L1 and IL-1R1 or IL-1β is shown in Figures 9A-9H (Figure 9A is huPD-L1-F coated with IL-1R1-His, Figure 9B is huPD-L1-Fc coated with huPD-L1-His, Figure 9C is huPD-L1-F coated with huIL-1β-His, and Figure 9D is huPD-L1-Fc coated with huIL-1β-His), among which BsAb1, BsAb4, BsAb6, BsAb11, BsAb13, BsAb5, BsAb26, BsAb27, BsAb28, and BsAb29 simultaneously bind to PD-L1 and IL-1R1 or IL-1β antigens with high affinity.

[0156] The amino acid sequences mentioned herein are as follows.

Claims

1. A bispecific antibody comprising a first portion targeting PD-L1 and a second portion targeting IL-1, wherein the first portion comprises an anti-PD-L1 antibody or an antigen-binding fragment thereof, wherein the anti-PD-L1 antibody comprises HCDR1, HCDR2 and HCDR3 from the heavy chain variable region (VH) shown in SEQ ID NO: 17 and LCDR1, LCDR2 and LCDR3 from the light chain variable region (VL) shown in SEQ ID NO:

18.

2. The bispecific antibody of claim 1, wherein the anti-PD-L1 antibody comprises the sequence shown in SEQ ID NO: 17 or an amino acid sequence having at least 90% sequence identity thereto and the sequence shown in SEQ ID NO: 18 or an amino acid sequence having at least 90% sequence identity thereto.

3. The bispecific antibody according to claim 1 or 2, wherein the heavy chain constant region of the anti-PD-L1 antibody is derived from IgG1, and the light chain constant region of the anti-PD-L1 antibody is derived from a kappa light chain.

4. The bispecific antibody of any one of claims 1 to 3, wherein the second portion comprises the extracellular binding domain of the IL-1 receptor (IL-1R) or a variant thereof. 5 . The bispecific antibody according to claim 1 , wherein the second portion comprises the sequence shown in SEQ ID NO: 14 or an amino acid sequence having at least 90% sequence identity thereto.

6. The bispecific antibody according to any one of claims 1 to 5, wherein the second portion is two, which are respectively connected to the N terminus of the VH of the anti-PD-L1 antibody, the N terminus of the VL of the anti-PD-L1 antibody, the C terminus of the heavy chain constant region of the anti-PD-L1 antibody, or the C terminus of the light chain constant region of the anti-PD-L1 antibody through the same or different connecting sequences.

7. The bispecific antibody of any one of claims 1 to 6, wherein the second portion is one, connected to the N-terminus of the VH of the anti-PD-L1 antibody, the N-terminus of the VL of the anti-PD-L1 antibody, the C-terminus of the heavy chain constant region of the anti-PD-L1 antibody, or the C-terminus of the light chain constant region of the anti-PD-L1 antibody through a linker sequence.

8. The bispecific antibody according to any one of claims 1 to 7, wherein the first portion is further connected to an antigen-binding fragment in Fab form of the anti-PD-L1 antibody at the C-terminus of the heavy chain constant region of the anti-PD-L1 antibody via a linker sequence. 9 . The bispecific antibody of claim 1 , wherein the second portion is an anti-IL-1β antibody or an antigen-binding fragment thereof.

10. The bispecific antibody of any one of claims 1 to 9, wherein the anti-IL-1β antibody comprises HCDR1, HCDR2 and HCDR3 from VH shown in SEQ ID NO: 15 and LCDR1, LCDR2 and LCDR3 from VL shown in SEQ ID NO:

16.

11. The bispecific antibody of any one of claims 1 to 10, wherein the anti-IL-1β antibody comprises the sequence of SEQ ID NO: 15 or an amino acid sequence having at least 90% sequence identity thereto and the sequence of SEQ ID NO: 16 or an amino acid sequence having at least 90% sequence identity thereto. 12 . The bispecific antibody according to claim 1 , wherein the heavy chain constant region of the anti-IL-1β antibody is derived from IgG1, and the light chain constant region of the anti-PD-L1 antibody is derived from a kappa light chain. 13 . The bispecific antibody according to claim 1 , wherein the antigen-binding fragment of the anti-IL-1β antibody is in the form of Fab or scFv. 14 . The bispecific antibody according to claim 1 , wherein the heavy chain constant region of the anti-PD-L1 antibody and / or the heavy chain constant region of the anti-IL-1β antibody is mutated to form a Knob-hole binding between the heavy chain constant regions.

15. The bispecific antibody according to any one of claims 1 to 14, wherein the first part and the second part are connected via the same or different linker sequences, preferably, the linker sequence is selected from (G4S)4G, (G4S)3G, (G4S)4 and (G4S)3.

16. The bispecific antibody of any one of claims 1 to 15, wherein the heavy chain of the anti-PD-L1 antibody comprises the sequence shown in SEQ ID NO: 9 or an amino acid sequence having at least 90% sequence identity thereto, and the light chain of the anti-PD-L1 antibody comprises the sequence shown in SEQ ID NO: 8 or an amino acid sequence having at least 90% sequence identity thereto.

17. The bispecific antibody of any one of claims 1 to 16, wherein the heavy chain of the anti-IL-1β antibody comprises the sequence shown in SEQ ID NO: 7 or an amino acid sequence having at least 90% sequence identity thereto, and the light chain of the anti-IL-1β antibody comprises the sequence shown in SEQ ID NO: 6 or an amino acid sequence having at least 90% sequence identity thereto.

18. The bispecific antibody of any one of claims 1 to 17, wherein the antigen-binding fragment of the anti-PD-L1 antibody in scFv form comprises the sequence shown in SEQ ID NO: 65 or an amino acid sequence having at least 90% sequence identity thereto.

19. The bispecific antibody according to any one of claims 1 to 18, wherein the antigen-binding fragment of the anti-IL-1β antibody in scFv form comprises the sequence shown in SEQ ID NO: 64 or an amino acid sequence having at least 90% sequence identity thereto.

20. The bispecific antibody according to any one of claims 1 to 19, which has any of the schematic antibody structures in Figures 1A to 1I.

21. The bispecific antibody according to any one of claims 1 to 19, which has any of the schematic antibody structures in Figures 2A to 2J.

22. The bispecific antibody according to any one of claims 1 to 21, wherein the extracellular binding domain of the IL-1 receptor (IL-1R) or a variant thereof is linked to an Fc fragment at its C-terminus.

23. The bispecific antibody of any one of claims 1-22, wherein the heavy chain constant region and / or the Fc fragment comprises an N297A mutation.

24. The bispecific antibody according to any one of claims 1 to 23, wherein the heavy chain constant region and / or the Fc fragment are from human IgG1.

25. The bispecific antibody of any one of claims 1-24, wherein the heavy chain constant region comprises the sequence shown in SEQ ID NO: 68, and the Fc fragment comprises the sequence shown in SEQ ID NO:

67.

26. The bispecific antibody of any one of claims 1-25, wherein the second portion comprises the sequence shown in SEQ ID NO: 10 or 66.

27. The bispecific antibody of any one of claims 1 to 26, wherein the bispecific antibody comprises a polypeptide chain listed in any row of Table 1.

28. The bispecific antibody of any one of claims 1 to 27, wherein the bispecific antibody comprises: 1) a polypeptide chain having a sequence shown in SEQ ID NO: 25 and a polypeptide chain having a sequence shown in SEQ ID NO: 26; 2) a polypeptide chain having a sequence shown in SEQ ID NO: 25 and a polypeptide chain having a sequence shown in SEQ ID NO: 30; 3) a polypeptide chain having a sequence shown in SEQ ID NO: 32 and a polypeptide chain having a sequence shown in SEQ ID NO: 28; 4) a polypeptide chain having a sequence as shown in SEQ ID NO: 40, a polypeptide chain having a sequence as shown in SEQ ID NO: 39, and a polypeptide chain having a sequence as shown in SEQ ID NO: 28; 5) a polypeptide chain having a sequence shown in SEQ ID NO: 43 and a polypeptide chain having a sequence shown in SEQ ID NO: 44; 6) a polypeptide chain having a sequence shown in SEQ ID NO: 45 and a polypeptide chain having a sequence shown in SEQ ID NO: 46; 7) a polypeptide chain having a sequence as shown in SEQ ID NO: 33, a polypeptide chain having a sequence as shown in SEQ ID NO: 28, a polypeptide chain having a sequence as shown in SEQ ID NO: 50, and a polypeptide chain having a sequence as shown in SEQ ID NO: 51; or 8) a polypeptide chain having a sequence shown in SEQ ID NO: 62 and a polypeptide chain having a sequence shown in SEQ ID NO: 63; 9) a polypeptide chain having a sequence shown in SEQ ID NO: 69 and a polypeptide chain having a sequence shown in SEQ ID NO: 30; 10) a polypeptide chain having a sequence shown in SEQ ID NO: 70 and a polypeptide chain having a sequence shown in SEQ ID NO: 28; 11) a polypeptide chain having a sequence as shown in SEQ ID NO: 71 and a polypeptide chain having a sequence as shown in SEQ ID NO: 46; or 12) A polypeptide chain having a sequence shown by SEQ ID NO: 72 and a polypeptide chain having a sequence shown by SEQ ID NO:

63.

29. A nucleic acid molecule encoding the bispecific antibody or polypeptide chain thereof according to any one of claims 1 to 28.

30. An expression vector comprising the nucleic acid molecule of claim 29.

31. A pharmaceutical composition comprising: 1) The bispecific antibody according to any one of claims 1 to 28, the nucleic acid molecule according to claim 29, or the expression vector according to claim 30; as well as 2) Pharmaceutically acceptable carrier.

32. Use of the bispecific antibody according to any one of claims 1 to 28, the nucleic acid molecule according to claim 29, or the expression vector according to claim 30 in the preparation of a medicament for treating a tumor.

33. The use of claim 32, wherein the tumor is selected from malignant melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, gastric cancer, breast cancer, pancreatic cancer and lung cancer.

34. A method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of the bispecific antibody of any one of claims 1-28, the nucleic acid molecule of claim 29, the expression vector of claim 30, or the pharmaceutical composition of claim 31.

35. The method of claim 34, wherein the tumor is selected from the group consisting of malignant melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, gastric cancer, breast cancer, pancreatic cancer, and lung cancer.